Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$1.66MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Martin Babler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 237
- Beta
- -0.67
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.17
Financials
Revenue
$1.66M-90.4%Net Income
$-142.22MEBITDA
$-148.78MFree Cash Flow
$-81.74MEPS (diluted)
$-1.11Shares Outstanding (diluted)
127.69M+146.3%Operating Expenses
$108.69MCash & Debt
$502.29MReturn of Capital
$0.00Revenue by Segment (annual)
$24.05MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $24.05M | $-243.32M | $-2.32 |
| 2024 | $0.00 | $-294.23M | $-10.38 |
| 2023 | $0.00 | $-154.99M | $-2.99 |
| 2022 | $0.00 | $-111.93M | $-14.93 |
Valuation
ALMShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+600.00%Social Signal Score
Mentions (8)
- Newsseekingalpha.com·21d ago·Positive
Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Alumis to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
View source ↗ - Newsseekingalpha.com·34d ago·Negative
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The recent share price crash, driven by a lupus trial failure, is significant but may not erase envudeucitinib's potential.
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
View source ↗ - Newsmarketbeat.com·34d ago·Negative
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients with a high interferon gene signature, a subgroup it plans to emphasize in future development discussions with regulators.
View source ↗ - Newsreuters.com·35d ago·Negative
Alumis eyes late-stage lupus study despite trial miss Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a mid-stage trial.
View source ↗ - Newsglobenewswire.com·35d ago·Positive
…soriasis in 4Q 2026 – – Conference call and webcast scheduled for September 1 at 8:30 am EDT – SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the ove…
View source ↗ - Newszacks.com·55d ago·Negative
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026 PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.73 per share
Typical surprise -15.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.11 vs $-0.77miss
- Thu, May 14$-0.74 vs $-0.74beat
- Thu, Mar 19$-0.95 vs $-0.97beat
- Thu, Nov 13$-1.06 vs $-0.92miss
- Wed, Aug 13$-1.17 vs $-1.11miss
- Wed, May 14$-1.82 vs $-1.47miss
Estimates and results for ALMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALMS officers and directors.
- Bought
- $61.7m
- Sold
- $1.5m
40 trades
9 trades
- Akkaraju Srinivasbought
- Akkaraju Srinivassold
- Akkaraju Srinivasbought
- Akkaraju Srinivassold
- Akkaraju Srinivasbought
- Akkaraju Srinivasbought
- Schroer John R.sold
- Pangali Sanamsold
51 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALMS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.